| Recombinant erythropoietin therapy in cancer patients |
| HF Bunn |
|
JCO Jun 1 1990: 949–951.
[PDF]
|
 |
| Chemotherapy for advanced aggressive lymphoma: more is better ...isn't it? |
| DL Longo |
|
JCO Jun 1 1990: 952–955.
[PDF]
|
|
|
Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration |
| |
W Oster, F Herrmann, H Gamm, G Zeile, A Lindemann, G Muller, T Brune, HP Kraemer, and R Mertelsmann |
| |
JCO Jun 1 1990: 956–962.
[Abstract]
[PDF]
|
|
|
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis |
| |
LW Kwak, J Halpern, RA Olshen, and SJ Horning |
| |
JCO Jun 1 1990: 963–977.
[Abstract]
[PDF]
|
|
|
Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site |
| |
M Korbling, R Holle, R Haas, W Knauf, B Dorken, AD Ho, R Kuse, H Pralle, TM Fliedner, and W Hunstein |
| |
JCO Jun 1 1990: 978–985.
[Abstract]
[PDF]
|
|
|
Immunobiologic factors predictive of clinical outcome in diffuse large- cell lymphoma |
| |
DJ Slymen, TP Miller, SM Lippman, CM Spier, DP Kerrigan, JA Rybski, CS Rangel, LC Richter, and TM Grogan |
| |
JCO Jun 1 1990: 986–993.
[Abstract]
[PDF]
|
|
|
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia |
| |
HM Kantarjian, RS Walters, MJ Keating, TL Smith, S O'Brien, EH Estey, YO Huh, J Spinolo, K Dicke, and B Barlogie |
| |
JCO Jun 1 1990: 994–1004.
[Abstract]
[PDF]
|
|
|
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16 |
| |
B Fisher, C Redmond, S Legault-Poisson, NV Dimitrov, AM Brown, DL Wickerham, N Wolmark, RG Margolese, D Bowman, and AG Glass |
| |
JCO Jun 1 1990: 1005–1018.
[Abstract]
[PDF]
|
|
|
Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women |
| |
T Fornander, LE Rutqvist, HE Sjoberg, L Blomqvist, A Mattsson, and U Glas |
| |
JCO Jun 1 1990: 1019–1024.
[Abstract]
[PDF]
|
|
|
Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay |
| |
FA Holmes, HA Fritsche, JW Loewy, AM Geitner, RC Sutton, AU Buzdar, and GN Hortobagyi |
| |
JCO Jun 1 1990: 1025–1035.
[Abstract]
[PDF]
|
|
|
Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study |
| |
M Nardi, F Cognetti, CF Pollera, MD Giulia, A Lombardi, G Atlante, and F Calabresi |
| |
JCO Jun 1 1990: 1036–1041.
[Abstract]
[PDF]
|
|
|
Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years |
| |
MP Dearing, SM Steinberg, R Phelps, MJ Anderson, JL Mulshine, DC Ihde, and BE Johnson |
| |
JCO Jun 1 1990: 1042–1049.
[Abstract]
[PDF]
|
|
|
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors |
| |
CJ Logothetis, FH Dexeus, L Finn, A Sella, RJ Amato, AG Ayala, and RG Kilbourn |
| |
JCO Jun 1 1990: 1050–1055.
[Abstract]
[PDF]
|
|
|
Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma |
| |
IW Dimery, SS Legha, M Shirinian, and WK Hong |
| |
JCO Jun 1 1990: 1056–1062.
[Abstract]
[PDF]
|
|
|
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy |
| |
J Bonneterre, B Chevallier, R Metz, P Fargeot, E Pujade-Lauraine, M Spielmann, M Tubiana-Hulin, D Paes, and J Bons |
| |
JCO Jun 1 1990: 1063–1069.
[Abstract]
[PDF]
|
|
|
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma |
| |
JM Kirkwood, MS Ernstoff, T Trautman, G Hebert, Y Nishida, CA Davis, J Balzer, S Reich, J Schindler, and SA Rudnick |
| |
JCO Jun 1 1990: 1070–1082.
[Abstract]
[PDF]
|
|
|
Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer |
| |
GE Goodman, I Hellstrom, L Brodzinsky, C Nicaise, B Kulander, D Hummel, and KE Hellstrom |
| |
JCO Jun 1 1990: 1083–1092.
[Abstract]
[PDF]
|
|
|
A phase I clinical trial and pharmacokinetic evaluation of liposome- encapsulated doxorubicin |
| |
A Rahman, J Treat, JK Roh, LA Potkul, WG Alvord, D Forst, and PV Woolley |
| |
JCO Jun 1 1990: 1093–1100.
[Abstract]
[PDF]
|
|
|
Etoposide kinetics in patients with obstructive jaundice |
| |
KR Hande, SN Wolff, FA Greco, JD Hainsworth, G Reed, and DH Johnson |
| |
JCO Jun 1 1990: 1101–1107.
[Abstract]
[PDF]
|
|
|
Chemoembolization for hepatocellular carcinoma |
| |
AP Venook, RJ Stagg, BJ Lewis, JL Chase, EJ Ring, TP Maroney, and DC Hohn |
| |
JCO Jun 1 1990: 1108–1114.
[Abstract]
[PDF]
|
|
| MTX clearance is more important for intermediate-risk ALL |
| WE Evans, MJ Schell, and CH Pui |
|
JCO Jun 1 1990: 1115–1116.
[PDF]
|
|
| Hydrazine sulfate in nonsmall-cell lung cancer |
| J Gold |
|
JCO Jun 1 1990: 1117–1118.
[PDF]
|
|
| Inadvertant omission of leucovorin rescue in a report on treatment of gastric lymphoma |
| J Lin |
|
JCO Jun 1 1990: 1118a.
[PDF]
|
|
| Prognostic significance of staging in gastric lymphoma |
| CR Thomas, Jr |
|
JCO Jun 1 1990: 1118b–1119.
[PDF]
|
|
| Hypersensitivity reactions to CHIP |
| CJ Rodenburg, J van Ulsen, C Seynaeve, and G Stoter |
|
JCO Jun 1 1990: 1119.
[PDF]
|
|
